---
schema_version: "secwatch.filing_event.v1"
accession: "0001323885-21-000048"
form_type: "8-K"
ticker: "ATRC"
cik: "0001323885"
company_name: "AtriCure, Inc."
filed_at: "2021-11-03T23:59:59+00:00"
generated_at: "2026-06-28T13:46:19.216523+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# AtriCure Q3 revenue $70.5M, +28.7% YoY; adj EPS -$0.23; FY guide reaffirmed

## Summary
- Revenue $70.5M, up 28.7% YoY (28.6% constant currency); U.S. $57.5M (+28.7%), intl $12.9M (+28.5%).
- GAAP income from operations $98.7M vs loss $4.0M, driven by $189.9M fair value credit and $82.3M impairment charge.
- Adjusted EBITDA $0.7M positive vs $4.2M positive; adjusted loss per share $0.23 vs $0.11 loss.
- Maintains FY2021 revenue guidance $270-275M (~31-33% growth); adj EBITDA loss ~$10M; adj EPS loss ~$1.20.
- CEO cites growth in Cryo Nerve Block and Hybrid AF accounts; delta variant impacts felt across the country.

## SEC filing metadata
- accession: 0001323885-21-000048
- form_type: 8-K
- ticker: ATRC
- cik: 0001323885
- company_name: AtriCure, Inc.
- filed_at: 2021-11-03T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1323885/000132388521000048/0001323885-21-000048-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1323885/000132388521000048/atrc-20211103.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001323885-21-000048
- JSON: https://secwatch.observer/filing/0001323885-21-000048.json
- Plain text: https://secwatch.observer/filing/0001323885-21-000048.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.